Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$3.34 - $4.29 $4.75 Million - $6.1 Million
-1,421,238 Reduced 59.77%
956,456 $3.48 Million
Q3 2023

Oct 26, 2023

SELL
$3.91 - $5.45 $9.29 Million - $13 Million
-2,376,350 Reduced 49.99%
2,377,694 $9.82 Million
Q2 2023

Aug 10, 2023

BUY
$3.72 - $4.79 $10.7 Million - $13.8 Million
2,874,373 Added 152.92%
4,754,044 $19.3 Million
Q1 2023

May 04, 2023

BUY
$3.95 - $5.63 $356,021 - $507,443
90,132 Added 5.04%
1,879,671 $7.71 Million
Q4 2022

Feb 03, 2023

BUY
$3.02 - $5.37 $42,068 - $74,804
13,930 Added 0.78%
1,789,539 $9.43 Million
Q3 2022

Oct 25, 2022

SELL
$2.99 - $4.35 $6.76 Million - $9.83 Million
-2,260,826 Reduced 56.01%
1,775,609 $5.49 Million
Q2 2022

Jul 29, 2022

SELL
$2.67 - $4.77 $858,810 - $1.53 Million
-321,652 Reduced 7.38%
4,036,435 $15.4 Million
Q1 2022

Apr 29, 2022

SELL
$2.62 - $4.45 $762,116 - $1.29 Million
-290,884 Reduced 6.26%
4,358,087 $16 Million
Q4 2021

Feb 02, 2022

BUY
$4.05 - $5.37 $4.77 Million - $6.32 Million
1,177,145 Added 33.91%
4,648,971 $20.3 Million
Q3 2021

Oct 28, 2021

BUY
$3.89 - $5.48 $2.3 Million - $3.24 Million
591,996 Added 20.56%
3,471,826 $15.1 Million
Q2 2021

Jul 29, 2021

BUY
$3.61 - $5.45 $10.4 Million - $15.7 Million
2,879,830 New
2,879,830 $15.7 Million
Q4 2020

Jan 29, 2021

SELL
$1.79 - $4.04 $5.23 Million - $11.8 Million
-2,922,488 Closed
0 $0
Q3 2020

Oct 28, 2020

BUY
$1.56 - $2.08 $2.05 Million - $2.73 Million
1,314,753 Added 81.78%
2,922,488 $5.49 Million
Q2 2020

Jul 28, 2020

BUY
$0.94 - $2.21 $1.51 Million - $3.55 Million
1,607,735 New
1,607,735 $2.81 Million

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.57B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Emerald Mutual Fund Advisers Trust Portfolio

Follow Emerald Mutual Fund Advisers Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Mutual Fund Advisers Trust, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Mutual Fund Advisers Trust with notifications on news.